UK Markets closed
  • FTSE 100

    6,915.75
    +30.43 (+0.44%)
     
  • FTSE 250

    22,251.26
    +90.66 (+0.41%)
     
  • AIM

    1,236.50
    +6.64 (+0.54%)
     
  • GBP/EUR

    1.1517
    -0.0053 (-0.46%)
     
  • GBP/USD

    1.3706
    -0.0032 (-0.2316%)
     
  • BTC-GBP

    44,086.97
    +1,328.59 (+3.11%)
     
  • CMC Crypto 200

    1,235.89
    +45.20 (+3.80%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.03 (+0.89%)
     
  • CRUDE OIL

    59.34
    -0.26 (-0.44%)
     
  • GOLD FUTURES

    1,744.10
    -14.10 (-0.80%)
     
  • NIKKEI 225

    29,768.06
    +37.26 (+0.13%)
     
  • HANG SENG

    28,698.80
    +24.00 (+0.08%)
     
  • DAX

    15,234.16
    +57.76 (+0.38%)
     
  • CAC 40

    6,169.41
    +38.75 (+0.63%)
     

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020

  • Oops!
    Something went wrong.
    Please try again later.
·12-min read
  • Oops!
    Something went wrong.
    Please try again later.

Q4 GAAP revenue including Grant Revenue $26.1M; Q4 non-GAAP revenue $21.6M, an increase of 36% versus prior year

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2020.

"Responding to the pandemic crisis as well as advances in therapies to treat Alzheimer’s has accelerated our leadership of precision health and the proteomics revolution," said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. "There is a strong demand for ultra-sensitive protein analytical tools to support disease studies, diagnostics and drug development as the COVID focus shifts from battling the acute virus to the long-hauler impact of the virus on organ and overall human health (CNS, Cardiac, Respiratory, Immunology, etc). We enter 2021 on strong footing as we scale Quanterix to support this unprecedented opportunity."

Fourth Quarter 2020 Financial Highlights

Key financial results for the four quarter of 2020 are shown below:

  • Q4 GAAP total revenue, which includes Grant Revenue, was $26.1M versus prior year Q4 of $15.9M;

  • Q4 non-GAAP total revenue was $21.6M versus prior year Q4 of $15.9M, an increase of 36%;

  • Q4 GAAP product revenue was $15.7M versus prior year Q4 of $11.4M, an increase of 38%;

  • Q4 GAAP service and other revenue was $5.5M versus prior year Q4 of $4.3M, an increase of 28%

Full Year 2020 Financial Highlights

Key financial results for FY 2020 are shown below:

  • FY GAAP total revenue, which includes one-time License Revenue and Grant Revenue, was $86.4M versus prior year FY of $56.7M;

  • FY non-GAAP total revenue was $68.8M versus prior year FY of $56.7M, an increase of 21%;

  • FY GAAP product revenue was $44.0M versus prior year FY of $40.5M, an increase of 9%;

  • FY GAAP service and other revenue was $24.1M versus prior year FY of $16.1M, an increase of 50%

For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of Non-GAAP Financials" below.

Fourth Quarter and Full Year Business Highlights

  • Awarded an $18.2M contract with the NIH through its RADx initiative to accelerate the continued development and scale-up of a novel SARS-CoV-2 antigen test.

  • Received FDA Emergency Use Authorizations for novel SARS-CoV-2 antigen test (after year-end) and for semi-quantitative antibody test, underscoring our longstanding science-first mentality and deep dedication to the highest standards of quality and scientific rigor across our business.

  • Leveraging the unparalleled ultra-sensitivity of Simoa, enabled several leading researchers globally, including at the NIH, to begin tackling leading-edge COVID challenges, such as establishing potential for blood based anti-viral endpoints for new drug therapies and understanding the long-term complications of COVID-19.

  • Expanded our differentiated Neurology menu to include tau phosphorylated at threonine 181 (pTau-181), a highly specific biomarker for the study of Alzheimer’s disease pathology, in cerebral spinal fluid (CSF), serum and plasma as well as launched Neuro Multiplex assays associated with many neurodegenerative diseases. Our biomarker portfolio is now supporting leading Alzheimer’s programs globally and a growing body of research, including work published recently in The Lancet Neurology. This work suggests that blood pTau-181 levels could prove critical to predicting Alzheimer’s disease progression and differentiating the disease from other neurodegenerative disorders, marking a critical step toward AD early detection, clinical trial advancements, improved patient triaging and asymptomatic screening.

  • Novartis’ multiple sclerosis (MS) drug KESIMPTA® (ofatumumab), which utilized Nf-L as secondary endpoint, was approved by the FDA.

  • Quanterix’ Simoa technology was highlighted in a record 443 new publications in 2020, bringing total Simoa-specific inclusions to over 1,120. Also, was invited to present at several marquis symposiums showcasing our Precision Health vision and potential to catalyze asymptomatic medicine.

  • Instrument installed base increased by 34% in 2020 to 535, despite access challenges posed by COVID-19. This includes 93 HD-X placements with over 50% new installations and 84 new SR-X and SP-X placements.

  • Solidified Simoa’s technological leadership by achieving a 100x sensitivity improvement in a pilot of the digital enzyme-linked immunosorbent assay (ELISA) that powers the Company’s HD-X™ and SR-X™ Ultra-Sensitive Biomarker Detection Systems.

  • Entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories, to grant Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in-vitro diagnostic (IVD) applications.

  • Realized multi-category revenue opportunities with one of the largest multi-national, healthcare payor groups, with execution of multiple population surveillance studies, creating beachhead for our vision for the future of precision medicine, where early and non-invasive disease detection has the potential to transform life and healthcare costs.

  • Successfully raised ~$385 million in gross proceeds across 2020 and early-2021 through our follow-on offerings, further strengthening our balance sheet with growth capital.

  • William Geist joined Quanterix as Chief Operating Officer to help us sustain and grown our strong momentum across numerous digital biomarker platforms.

Conference Call

In conjunction with this announcement, Quanterix Corporation will host a conference call on March 2 at 4:30 p.m., EST. Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 4438067. A live webcast will also be available at: https://edge.media-server.com/mmc/p/tbpi32nd. The webcast will be available on the Company’s website, https://www.quanterix.com, for one year following completion of the call.

Financial Highlights

Quanterix Income Statement

in '000 USD

Q4 2020

Q4 2019

YTD 2020

YTD 2019

Product Revenue

15,732

11,431

44,017

40,491

Service and Other Revenue

5,498

4,302

24,129

16,059

Collaboration and License Revenue

408

184

11,809

184

Development Revenue

4,493

0

6,422

0

Total Revenue

26,131

15,917

86,377

56,734

Cost of Product Revenue

7,961

6,684

25,950

20,900

Cost of Services Revenue

3,120

2,368

11,245

8,998

Cost of License Revenue

0

0

1,000

0

Gross Profit

15,050

6,865

48,182

26,836

Gross Margin %

57.6%

43.1%

55.8%

47.3%

Research and Development

6,217

4,398

20,174

16,190

Selling, General and Administrative

18,766

13,953

59,592

52,246

Total Operating Expenses

24,983

18,351

79,766

68,436

Loss From Operations

-9,933

-11,486

-31,584

-41,600

Interest Income (Expense), net

-166

282

-273

627

Other Income (Expense), net

155

139

-49

-10

Tax

123

107

376

187

Net Loss

-9,821

-10,958

-31,530

-40,796

Weighted average shares outstanding was 31.7 million for Q4 2020 and 28.6 million for YTD 2020

Quanterix Balance Sheet

in '000 USD

At 12/31/20

At 12/31/19

Cash and Cash Equivalents

181,584

109,155

Accounts Receivable

17,184

10,906

Inventory

14,856

10,463

Prepaid Expenses and Other

5,981

2,137

Total Current Assets

219,605

132,661

Restricted Cash

1,000

1,026

Property and Equipment, Net

13,912

12,047

Intangible Assets, Net

13,716

14,307

Goodwill

10,460

9,353

Right-of-Use Assets

11,995

0

Other Non-Current Assets

357

557

Total Assets

271,045

169,951

Accounts Payable & Accrued Expenses

22,421

14,845

Deferred Revenue

5,421

4,697

Current Portion of Long Term Debt

7,673

75

Lease Liabilities

1,234

0

Other Current Liabilities

3,054

216

Total Current Liabilities

39,803

19,833

Deferred Revenue, Net of Current Portion

577

466

Long Term Debt, Net of Current Portion

0

7,587

Lease Liabilities, Net of Current Portion

21,891

0

Other Non-Current Liabilities

2,649

13,407

Total Liabilities

64,920

41,293

Total Stockholders’ Equity

206,125

128,658

Total Liabilities and Stockholders’ Equity

271,045

169,951

Use of Non-GAAP Financial Measures

To supplement the Company’s financial statements presented on a GAAP basis, the Company has provided certain non-GAAP financial measures, including non-GAAP revenue. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such measures are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’s operating performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth below.

Reconciliation of non-GAAP Financials

(In thousands)

2020

2019

2020

2019

Three months ended

Twelve months ended

December 31

December 31

Total revenue

$

26,131

$

15,917

$

86,377

$

56,734

License agreement revenue (Note 1)

$

(11,200

)

Grant revenue (Note 2)

$

(4,493

)

$

(6,422

)

Non-GAAP revenue

$

21,638

$

15,917

$

68,755

$

56,734

Gross profit

$

15,050

$

6,865

$

48,182

$

26,836

License agreement revenue (Note 1)

$

(11,200

)

Grant revenue (Note 2)

$

(4,493

)

$

(6,422

)

Acquisition-related purchase accounting charges (Note 3)

$

433

$

667

$

2,251

$

1,378

Cost of license revenue (Note 4)

$

1,000

Non-GAAP gross profit

$

10,990

$

7,532

$

33,811

$

28,214

GAAP gross margin %

57.6

%

43.1

%

55.8

%

47.3

%

Non-GAAP gross margin %

50.8

%

47.3

%

49.2

%

49.7

%

GAAP total operating expenses

$

24,983

$

18,351

$

79,766

$

68,436

Grant research and development expenses (Note 5)

$

(2,322

)

$

(3,625

)

Acquisition-related purchase accounting charges (Note 6)

$

(20

)

$

(20

)

$

(81

)

$

(41

)

Non-GAAP total operating expenses

$

22,641

$

18,331

$

76,060

$

68,395

GAAP loss from operations

$

(9,933

)

$

(11,486

)

$

(31,584

)

$

(41,600

)

Non-GAAP loss from operations

$

(11,651

)

$

(10,799

)

$

(42,249

)

$

(40,181

)

Note 1: During the twelve months ended December 31, 2020, we recognized $10.0 million in license revenue in connection with a non-exclusive license agreement with Abbott Laboratories. Also, during the twelve months ended December 31, 2020, we recognized $1.2 million in license revenue in connection with the previous agreements with Abbott Laboratories.

Note 2: During the three and twelve months ended December 31, 2020, we recognized $4.5 million and $6.4 million, respectively, in revenue in connection with our workplan 1 and workplan 2 awards under the National Institute of Health Rapid Acceleration of Diagnostics Program.

Note 3: During the three months ended December 31, 2020, we incurred $51 thousand of acquisition-related amortization of inventory valuation and $382 thousand of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics. During the twelve months ended December 31, 2020, we incurred $722 thousand of acquisition-related amortization of inventory valuation and $1,529 thousand of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics. During the three months ended December 31, 2019, we incurred $284 thousand of acquisition-related amortization of inventory valuation and $383 thousand of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics. During the twelve months ended December 31, 2019, we incurred $612 thousand of acquisition-related amortization of inventory valuation and $766 thousand of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics.

Note 4: During the twelve months ended December 31, 2020, we incurred $1.0 million in license fees in connection with our non-exclusive license agreement with Abbott Laboratories.

Note 5: During the three and twelve months ended December 31, 2020, we incurred $2.3 million and $3.6 million, respectively, in research and development expenses in connection with our workplan 1 and workplan 2 awards under the National Institute of Health Rapid Acceleration of Diagnostics Program.

Note 6: During the three and twelve months ended December 31, 2020, we incurred $20 thousand and $81 thousand, respectively, of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics. During three and twelve months ended December 31, 2019, we incurred $20 thousand and $41 thousand, respectively, of acquisition-related amortization of intangible assets adjustments in connection with our acquisition of UmanDiagnostics.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006101/en/

Contacts

Media
PAN Communications
Staci Didner, (407) 734-7325
quanterix@pancomm.com

Investor Relations:
Stephen Hrusovsky
(774) 278-0496
shrusovsky@quanterix.com